Ecopipam

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Ecopipam (SCH 39166) 是一种有效的、选择性、具有口服活性的多巴胺 D1/D5 受体拮抗剂，Ki 值分别为 1.2 nM 和 2.0 nM。Ecopipam 对 D2、D4、5-HT 和 α2a 受体 (Ki=0.98，5.52，0.08 和 0.73 μM) 显示出超过 40 倍的选择性。Ecopipam 可用于精神分裂症和肥胖症的研究。

Ecopipam (SCH 39166) is a potent, selective and orally active antagonist of dopamine D1/D5 receptor, with Kis of 1.2 nM and 2.0 nM, respectively. Ecopipam shows more than 40-flod selectivity over D2, D4, 5-HT, and α2a receptor (Ki=0.98, 5.52, 0.08, and 0.73 μM, respectively). Ecopipam can be used for the research of schizophrenia and obesity.

——

Animal Model:Male young adult Long-Evans rats injected with Nicotine Dosage:0.003, 0.01, 0.03, 0.1, 0.3 mg/kg Administration:A single s.c. 20 min before Nicotine (0.1 mg/kg)Result:Dose-dependently reduced pressing on both active and inactive levers.

——

GPCR/G Protein

Dopamine Receptor

Dopamine Receptor

——

——

112108-01-7

313.82

C19H20ClNO

>98% (HPLC)

——

CN1[C@@]2([C@@](C=3C(=CC(Cl)=C(O)C3)CC1)(C=4C(CC2)=CC=CC4)[H])[H]

——

(-20℃)

With Ice Pack

≥ 2 years